US 12,281,111 B2
Substituted pyrrolopyridine JAK inhibitors and methods of making and using the same
David Randolph Anderson, Salem, CT (US); Susan Landis Hockerman, Kirkwood, MO (US); James Robert Blinn, O'Fallon, MO (US); and Eric Jon Jacobsen, Chesterfield, MO (US)
Assigned to Aclaris Therapeutics, Inc., Wayne, PA (US)
Filed by ACLARIS THERAPEUTICS, INC., Wayne, PA (US)
Filed on Jul. 3, 2023, as Appl. No. 18/217,874.
Application 18/217,874 is a continuation of application No. 17/203,482, filed on Mar. 16, 2021, granted, now 11,739,086.
Application 17/203,482 is a continuation of application No. 16/179,695, filed on Nov. 2, 2018, granted, now 10,981,906, issued on Apr. 20, 2021.
Claims priority of provisional application 62/670,448, filed on May 11, 2018.
Claims priority of provisional application 62/581,428, filed on Nov. 3, 2017.
Prior Publication US 2024/0067643 A1, Feb. 29, 2024
This patent is subject to a terminal disclaimer.
Int. Cl. C07D 471/04 (2006.01); A61K 31/437 (2006.01); A61K 31/4545 (2006.01); A61K 45/06 (2006.01)
CPC C07D 471/04 (2013.01) [A61K 31/437 (2013.01); A61K 31/4545 (2013.01); A61K 45/06 (2013.01)] 7 Claims
 
1. A method of treating a JAK1- and/or JAK3-mediated disease in a subject in need thereof comprising: administering to the subject a therapeutically effective amount of a compound of Formula (I):

OG Complex Work Unit Chemistry
wherein:
R1 is —CO2R5;
R2 is H;
n is 1 or 2;
Ring A is substituted with one R3 substituents wherein R3 is selected from H or —C1-C4alkyl;
R4 is —C(O)—C1-C5alkyl, wherein the alkyl groups may be optionally substituted with —CN; and
R5 is —C1-C5alkyl,
a derivative thereof, or a combination thereof.